UroGen's ZUSDURI Revenue Surges 73% as Pipeline Advances
Event summary
- ZUSDURI generated $50.4 million in revenue in Q2 2026, up 73% quarter-over-quarter.
- UroGen received a new U.S. patent allowance extending protection for ZUSDURI and UGN-103 to July 2044.
- UGN-103 is on track for NDA submission in Q3 2026, with potential FDA approval in 2027.
- UroGen expects to initiate a Phase 1 trial for UGN-501 in Q4 2026.
The big picture
UroGen's strong Q2 2026 results highlight the growing commercial success of ZUSDURI, while strategic patent protections extend its market exclusivity. The company's advancing pipeline, particularly UGN-103 and UGN-501, positions it to capitalize on unmet needs in urothelial cancer treatment. Investors will watch closely as UroGen balances aggressive commercial expansion with sustained R&D investment.
What we're watching
- Commercial Momentum
- Whether ZUSDURI can sustain its rapid adoption rate and repeat prescriber growth.
- Regulatory Milestones
- The timeline for UGN-103's NDA submission and potential FDA approval in 2027.
- Pipeline Progress
- The initiation of Phase 1 trials for UGN-501 and its potential impact on high-grade NMIBC treatment.
Related topics